Approved Medications 2016
The following Medications have been new approved in 2016, by the Government. Review the the name of the Medication and its Indications.
Newely Approved Medications
Name | Indications |
Albiglutide | (Tanzeum) An injectable GLP-1 agonist for type 2 diabetes |
Apremilast (Otezla) | A phosphodiesterase 4 (PDE4) inhibitor for psoriatic arthritis |
Belinostat (Beleodaq) | A histone deacetylase inhibitor for advanced peripheral T-cell lymphoma |
Ceritinib (Zykadia) | A kinase inhibitor for treatment of certain type of metastatic non–small-cell lung cancer |
Cobicistat (Tybost) | Pharmaco-enhancing or “boosting” agent for antiviral drugs used in treatment of HIV infection |
Dalbavancin (Dalvance) | Antibiotic for treatment of adult patients with complicated skin and skin structure infections, including MRSA |
Dapagliflozin (Farxiga) | A sodium glucose co-transporter 2 (SGLT-2) inhibitor for type 2 diabetes |
Droxidopa (Northera) | A synthetic amino acid analogue for neurogenic orthostatic hypotension |
Dulaglutide (Trulicity) | A glucagon-like peptide receptor agonist for the treatment of type 2 diabetes |
Elvitegravir (Vitekta) | Integrase inhibitor for treatment of HIV-1 infection |
Empagliflozin (Jardiance) | An SGLT-2 inhibitor for type 2 diabetes |
Idelalisib (Zydelig) | A kinase inhibitor for treatment of chronic lymphocyticleukemia, relapsed follicular B-cell non-Hodgkin’s lymphoma, and relapsed small lymphocytic lymphoma |
Metreleptin (Myalept) | A leptin analogue for patients with lipodystrophy |
Naloxegol (Movantik) | A peripherally acting opioid receptor antagonist indicated for the treatment of opioid-induced constipation |
Olodaterol (StriverdiRespimat) | A long-acting beta agonist oral inhaler for COPD |
Oritavancin (Orbactiv) | An injectable lipoglycopeptide antibiotic for skin and skin structure infections |
Peginterferon beta-1a (Plegridy) | An interferon beta for treatment of relapsing forms of multiple sclerosis |
Pembrolizumab (Keytruda) | A human PD1-blocking antibody indicated for the treatment of metastatic melanoma |
Ramucirumab (Cyramza) | An angiogenesis inhibitor for gastric cancer |
Suvorexant (Belsomra) | An orexin receptor antagonist indicated for the treatment of insomnia |
Tedizolid (Sivextro) | An antibiotic for skin infections |
Umeclidinium (Incruse Ellipta) | New anticholinergic oral inhaler for maintenance treatment of COPD |
Vedolizumab (Entyvio) | An integrin receptor antagonist for treatment of Crohn’s disease and ulcerative colitis |
Vorapaxar (Zontivity) | An antiplatelet agent for pts with history of MI or with peripheral arterial disease (PAD) |